← All trials
NCT04678102
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2022
- First posted
- Dec 21, 2020
- Last posted
- Dec 21, 2020
- Enrollment
- 36
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Seoul National UniversityLead sponsor
- Seoul National UniversityReponsible party - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Pharos Life CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.